AIP
HAE icon

Ameritas Investment Partners’s Haemonetics HAE Stock Holding History

Ameritas Investment Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Buy
12,861
+368
+3% +$23.6K 0.03% 652
2026
Q1 		$704K Hold
12,493
– – 0.02% 729
2025
Q4 		$1M Sell
12,493
-566
-4% -$38K 0.03% 613
2025
Q3 		$636K Sell
13,059
-1,843
-12% -$114K 0.02% 739
2025
Q2 		$1.11M Sell
14,902
-179
-1% -$11.9K 0.04% 576
2025
Q1 		$958K Sell
15,081
-229
-1% -$15.6K 0.03% 622
2024
Q4 		$1.2M Sell
15,310
-193
-1% -$15.5K 0.04% 566
2024
Q3 		$1.25M Sell
15,503
-302
-2% -$24.4K 0.04% 549
2024
Q2 		$1.31M Sell
15,805
-402
-2% -$35.4K 0.04% 504
2024
Q1 		$1.38M Sell
16,207
-190
-1% -$14.9K 0.05% 496
2023
Q4 		$1.4M Buy
16,397
+39
+0.2% +$3.37K 0.05% 473
2023
Q3 		$1.47M Sell
16,358
-383
-2% -$34.2K 0.06% 394
2023
Q2 		$1.43M Sell
16,741
-84
-0.5% -$7.1K 0.05% 437
2023
Q1 		$1.39M Sell
16,825
-354
-2% -$28.7K 0.06% 436
2022
Q4 		$1.54M Hold
17,179
– – 0.06% 387
2022
Q3 		$1.27M Sell
17,179
-130
-0.8% -$9.33K 0.06% 415
2022
Q2 		$1.13M Sell
17,309
-147
-0.8% -$8.7K 0.05% 488
2022
Q1 		$1.1M Hold
17,456
– – 0.04% 585
2021
Q4 		$926K Hold
17,456
– – 0.03% 663
2021
Q3 		$1.23M Sell
17,456
-533
-3% -$33.6K 0.04% 515
2021
Q2 		$1.2M Buy
17,989
+3,956
+28% +$280K 0.04% 543
2021
Q1 		$1.56M Hold
14,033
– – 0.06% 395
2020
Q4 		$1.67M Sell
14,033
-320
-2% -$34.5K 0.08% 323
2020
Q3 		$1.25M Sell
14,353
-224
-2% -$19.6K 0.06% 379
2020
Q2 		$1.31M Sell
14,577
-4,013
-22% -$405K 0.06% 351
2020
Q1 		$1.85M Sell
18,590
-99
-0.5% -$10.7K 0.11% 191
2019
Q4 		$2.15M Buy
18,689
+22
+0.1% +$2.66K 0.1% 221
2019
Q3 		$2.35M Sell
18,667
-575
-3% -$73K 0.11% 190
2019
Q2 		$2.32M Hold
19,242
– – 0.11% 198
2019
Q1 		$1.68M Sell
19,242
-349
-2% -$31.7K 0.08% 288
2018
Q4 		$1.96M Buy
19,591
+140
+0.7% +$14.7K 0.11% 200
2018
Q3 		$2.23M Sell
19,451
-370
-2% -$38.3K 0.1% 223
2018
Q2 		$1.78M Buy
19,821
+15,273
+336% +$1.29M 0.09% 276
2018
Q1 		$333K Buy
4,548
+129
+3% +$8.85K 0.02% 853
2017
Q4 		$257K Hold
4,419
– – 0.01% 963
2017
Q3 		$190K Hold
4,419
– – 0.01% 1087
2017
Q2 		$175K Hold
4,419
– – 0.01% 1131
2017
Q1 		$179K Buy
+4,419
New +$173K 0.01% 1116
2015
Q2 		– Sell
-4,665
Closed -$210K – 1184
2015
Q1 		$210K Buy
+4,665
New +$195K 0.01% 985

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameritas Investment Partners's HAE Position: Q2 2026 in Review

Ameritas Investment Partners increased its Haemonetics (HAE) stake by 2.9% in Q2 2026, buying an estimated $23.6K and bringing the position to 12,861 shares worth $965K. The position accounts for 0.03% of the portfolio, ranked #652.

Ameritas Investment Partners first reported a position in HAE in Q1 2015 and has held it in 39 quarters since. The position peaked at $2.35M in Q3 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Ameritas Investment Partners held 12,861 shares of Haemonetics worth $965K as of Q2 2026.
  • Ameritas Investment Partners bought 368 Haemonetics shares in Q2 2026, an estimated $23.6K.
  • Haemonetics made up 0.03% of Ameritas Investment Partners's portfolio in Q2 2026, its #652 holding.
  • Ameritas Investment Partners first reported a position in Haemonetics in Q1 2015 and has held it in 39 quarters since.
  • Ameritas Investment Partners's Haemonetics position peaked at $2.35M in Q3 2019.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.